Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pathogenesis(pgns) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Li who wrote (80)	4/30/1998 12:46:00 AM
From: Ken M	Read Replies (1) \| Respond to of 228

It will be a mistake to sell at the open do not fall for this sucker play.

To: Bill Li who wrote (80)	4/30/1998 9:01:00 AM
From: Henry Niman	Respond to of 228

PGNS ask is already uo to $41. Here's what thestreet.com said last night: Evening Update: PathoGenesis Posts 1Q Earnings, Tops Expectation for Loss By Heather Moore and John J. Edwards III Staff Reporters 4/29/98 9:27 PM ET PathoGenesis (PGNS:Nasdaq) reported first-quarter earnings of 6 cents per share, soundly beating the seven-analyst expectation of a 9-cent loss versus the year-ago 43-cent loss. The company cited the success of its TOBI cystic fibrosis treatment. PathoGenesis said it now expects to be profitable in each quarter of 1998 and for the full year; current estimates call for a loss of 8 cents in the second quarter, a break-even result in the third quarter, a profit of 22 cents in the fourth quarter and a profit of 1 cent for the year.